Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

NCT07816185 is registered in ClinicalTrials.gov with Pulmovant, Inc. as lead sponsor.

NCT NCT07816185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Lead sponsor
Pulmovant, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
August 31, 2029
Enrollment
376 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, fibrosis, interstitial lung disease, pulmonary hypertension, vascular diseases